Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core working party for Asia-Pacific consensus on hepatitis B and C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 8, 2000, Pages 825-839

  Farrell, Gc ^a   Liaw, Y F ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CORTICOSTEROID; ENTECAVIR; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; RIBAVIRIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; ASIA; AUSTRALIA; CLINICAL PROTOCOL; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG INDICATION; HEALTH CARE ORGANIZATION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNIZATION; LIVER FIBROSIS; LIVER TRANSPLANTATION; NEW ZEALAND; PATIENT MONITORING; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

EID: 0033799182     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02324.x     Document Type: Article

References (64)

1. Epidemiology of hepatitis B virus infection in the Asia-Pacific region
2. Public health measures to control hepatitis B virus infection in the developing countries of Asia-Pacific region
3. Perinatal transmission of hepatitis B virus and its prevention
4. Natural history hepatitis B virus infection in children
5. Natural history of chronic hepatitis B virus infection
6. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
7. From hepatitis to hepatoma Lessons from type B viral hepatitis
8. Changes of serum hepatitis B viral DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children
9. Hepatitis B surface antigen and chronic hepatitis in infants born to asymptomatic carrier mothers
10. Vertical transmission of hepatitis B antigen in Taiwan
11. E Antigen in mother's serum as an indicator of vertical transmission
12. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
13. The development of cirrhosis in patients with chronic type B hepatitis
14. Natural history of chronic hepatitis B virus infection in Taiwan. Studies of hepatitis B virus DNA in serum
15. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan
16. Pathogenesis and clinical significance of acute exacerbation and remissions in patients with chronic hepatitis B virus infection
17. Current trends in therapy for chronic viral hepatitis
18. Interferon monotherapy in chronic hepatitis B
19. Role of steroid priming in the treatment of chronic hepatitis B
20. Long term follow-up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B
21. Long term beneficial effects of interferon therapy in patients with chronic hepatitis B virus infection
22. Treatment of chronic hepatitis B virus infection in special groups of patients: Decompensated cirrhosis, immunosuppressed and paediatric patients
23. Efficacy of thymosin α1 in patients with chronic type B hepatitis: A randomized controlled trial
24. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection
25. Nucleoside analogues in the treatment of chronic hepatitis B
26. Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
27. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
28. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
29. Treatment of chronic liver diseases with traditional Chinese medicine
30. Treatment chronic hepatitis B in China
31. Transmission of hepatitis C virus in Asia: Past and present perspectives
32. Public health challenges in hepatitis C virus infection
33. Natural history of acute hepatitis C
34. Natural history of hepatitis C virus infection
35. Natural history of chronic hepatitis C
36. Dilemma of the natural history of hepatitis C
37. Which patients with hepatitis C develop liver complications?
38. Health-related quality of life in chronic hepatitis C Impact of disease and treatment response
39. Case selection for interferon treatment of hepatitis C
40. Where does treatment fit into the strategy to control hepatitis C
41. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C. Flaws in the cure, or a clue to the flaws?
42. Grading and staging the histopathological lesion of chronic hepatitis: The Knodell Hepatitis Activity Index and beyond
43. Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about and what we still need to know
44. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C
45. First line treatment for hepatitis C: Combination interferon/ribavirin versus interferon monotherapy
46. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
47. Therapy of hepatitis C. Overview
48. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
49. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C
50. Management of hepatitis C
51. French consensus conference on hepatitis C. Screening treatment
52. EASL International consensus conference on hepatitis C
53. Acute hepatitis C
54. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: How does this modify the treatment course?
55. Adverse effects and other safety aspects of hepatitis C antivitals
56. Hepatitis C: Retreatment and treatment of patients with renal failure
57. What should we advise about adjunctive therapies, including herbal medicines for chronic hepatitis C?
58. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection; a randomized, placebo-controlled double-blind trial
59. Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling hepatitis B virus before and after transplantation
60. Indications and needs for living-related transplantation in adults
61. Fulminant hepatitis B in patients with chronic HBV infection
62. Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma
63. Pre- and post-transplant treatment of hepatitis C